Sickle cell anemia treatment does not increase malaria risk in Africa

October 19, 2017, American Society of Hematology

The drug hydroxyurea does not appear to increase the risk of malaria infection in patients with sickle cell anemia who live in malaria-endemic regions, according to a study published online today in Blood, a Journal of the American Society of Hematology (ASH).

Sickle cell anemia (SCA) is an inherited disorder characterized by abnormal red blood cells that stick together in patients' blood vessels, blocking the blood flow to organs, which can lead to severe pain, organ failure, stroke, and even death. In low-resource regions of sub-Saharan Africa, more than 50 percent of with SCA die before the age of five.

Hydroxyurea, a medicine recommended for children with SCA in high-resource settings like the United States and Europe, is not widely prescribed in sub-Saharan Africa, which has the highest burden of SCA in the world. This is partly because of a lack of data that will be effective and safe in low-resource regions. In particular, some research suggests that hydroxyurea could make people with SCA more susceptible to , a serious and sometimes fatal disease spread by mosquitoes and common across sub-Saharan Africa.

"Research has been unclear over whether the changes in immune response caused by hydroxyurea could increase the risk of malaria," said Chandy John, MD, of Indiana University School of Medicine, principal investigator of the trial. "Because hydroxyurea provides such positive outcomes for people in high-resource regions, we want to be sure that this drug is safe for children in low-resource, malaria-prone settings.

To understand if hydroxyurea use is associated with higher rates of malaria in sub-Saharan Africa, researchers from the United States and Uganda established the Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM) trial, a year-long, randomized double-blinded placebo-controlled study.

NOHARM was led on the ground by co-principal investigator Robert O. Opoka, MMED, of Makerere University in Kampala, Uganda. The team recruited 208 children aged 1-4 years and randomly assigned them into one of two treatment arms, in which they received either a fixed dose of hydroxyurea or a placebo for a full year. All patients also received standard bed netting and anti-malaria medication.

"Not only were we pleased to see that the overall incidence of malaria was low, but there was also no correlation between hydroxyurea treatment and the rate or severity of malaria," said co-principal investigator and head of data coordination Russell E. Ware, MD, PhD, of Cincinnati Children's Hospital Medical Center.

The treatment arms did not differ in terms of incidence or severity of or other adverse events. Three children on hydroxyurea experienced a total of five malaria episodes, while seven of those receiving placebo had a total of seven malaria episodes. Two children in the hydroxyurea arm died, one from presumed sepsis and the other from unknown sudden death; one child in the placebo arm died, presumably from sepsis.

Children receiving hydroxyurea also had lower rates of pain crises and hospitalizations. "Because the children prescribed hydroxyurea experienced significantly better outcomes without any increase in malaria risk, we are incredibly encouraged to further explore the drug's use in sub-Saharan Africa," said Dr. Ware.

As overall malaria incidence was low in the NOHARM study population, it will be important to monitor the rate and severity of malaria with hydroxyurea use in areas of higher malaria transmission. Drs. John, Ware, and Opoka are currently in the process of recruiting participants for a follow-up study to gauge the optimal dose for children with SCD in resource-limited, malaria-prone regions.

"It is our hope that these research studies can help establish hydroxyurea as the standard of care for children with sickle cell disease in Africa," said Dr. John.

Explore further: Rapid diagnostic test helps distinguish between severe and uncomplicated malaria in Africa

Related Stories

Rapid diagnostic test helps distinguish between severe and uncomplicated malaria in Africa

August 24, 2017
Malaria is a leading cause of death for children living in Sub-Saharan Africa. Many children in rural areas seek care at local community health clinics, but these clinics lack reliable tests to distinguish severe and uncomplicated ...

Drug treatment means better, less costly care for children with sickle cell disease

September 11, 2013
The benefits of hydroxyurea treatment in people with sickle cell disease are well known—fewer painful episodes, fewer blood transfusions and fewer hospitalizations. Now new research from the Johns Hopkins Children's Center ...

Hydroxyurea improves lung function in children with sickle cell disease

May 18, 2016
For the first time, researchers were able to demonstrate that children diagnosed with sickle cell disease showed improvement in lung function after treatment with hydroxyurea, a treatment that is underused despite its demonstrated ...

Successful outcome prompts early end to sickle cell anemia clinical trial

November 19, 2014
Conclusive data show that hydroxyurea therapy offers safe and effective disease management of sickle cell anemia (SCA) and reduces the risk of stroke, prompting early termination by the National Heart Lung and Blood Institute ...

Pediatric sickle cell study stopped early due to positive results

January 4, 2016
A national sickle cell disease study involving Medical University of South Carolina researchers found that for some children with sickle cell disease, the drug hydroxyurea is as effective as blood transfusions to reduce blood ...

Recommended for you

Past encounters with the flu shape vaccine response

February 20, 2018
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

IFN-mediated immunity to influenza A virus infection influenced by RIPK3 protein

February 15, 2018
Each year, influenza kills half a million people globally with the elderly and very young most often the victims. In fact, the Centers for Disease Control and Prevention reported 37 children have died in the United States ...

Flu shot only 36 percent effective, making bad year worse (Update)

February 15, 2018
The flu vaccine is doing a poor job protecting older Americans and others against the bug that's causing most illnesses.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.